trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Polypharmacy in middle-aged and elderly individuals increases the risk of drug interactions and adverse immune responses.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
4 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that Polypharmacy in middle-aged and elderly individuals increases the risk of drug interactions and adverse immune responses?

Yes. Evidence strongly indicates that polypharmacy among middle-aged and elderly populations significantly increases the risk of adverse drug events and dangerous drug interactions.

Verdict: SUPPORTED · 4 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently supports the claim that polypharmacy in older and middle-aged individuals elevates the risk of adverse drug interactions and negative health events due to age-related physiological changes and multiple concurrent drug exposures. Multiple papers (e.g., [0], [2], [10], [11]) explicitly associate polypharmacy with heightened adverse drug reactions and serious outcomes. Therefore, the verdict is SUPPORTED.

Evidence for · 4
Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients
2021
Demonstrates that antipsychotic polypharmacy significantly increases the risk of adverse drug events in psychiatric patients.
Get citation
Ayani, N., Morimoto, T., Sakuma, M., Kikuchi, T., Watanabe, K., & Narumoto, J. (2021). Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients. doi.org. https://doi.org/10.1097/jcp.0000000000001416

See more details
More for · 3
Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions.
2026
Highlights how compounded polypharmacy and multimorbidity increase risks and vulnerability to adverse outcomes in older adults.
Get citation
V, K., L, N., C, F., V, K., K, T., & K, T. (2026). Cardio-Oncology in Older Adults: Evidence Gaps, Geriatric Considerations, and Future Directions.. doi.org. https://doi.org/10.3390/jcm15176592

Advanced Drug Delivery Strategies in Geriatric Patients with Polypharmacy: Integrating Pharmacokinetics, Personalized Medicine, and Emerging Technologies.
2026
Notes that widespread polypharmacy in older adults reduces the effectiveness and safety of conventional medication approaches.
Get citation
D, B., K, B., BP, G., K, D., & D, A. (2026). Advanced Drug Delivery Strategies in Geriatric Patients with Polypharmacy: Integrating Pharmacokinetics, Personalized Medicine, and Emerging Technologies.. doi.org. https://doi.org/10.3390/jcm15114359

Cross-national disparities in drug interaction reporting and assessment between Switzerland and Austria: A retrospective, registry-based study using pharmacovigilance data.
2026
Shows that polypharmacy is strongly associated with serious adverse drug outcomes across national registries.
Get citation
M, R., A, M. D. l. T., R, B., AM, B., & S, W. (2026). Cross-national disparities in drug interaction reporting and assessment between Switzerland and Austria: A retrospective, registry-based study using pharmacovigilance data.. doi.org. https://doi.org/10.1371/journal.pone.0356774

What does the evidence say?

The retrieved literature consistently supports the claim that polypharmacy in older and middle-aged individuals elevates the risk of adverse drug interactions and negative health events due to age-related physiological changes and multiple concurrent drug exposures. Multiple papers (e.g., [0], [2], [10], [11]) explicitly associate polypharmacy with heightened adverse drug reactions and serious outcomes. Therefore, the verdict is SUPPORTED.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work